Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.
Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, Yuan M, Liu N, Chen H, Zhang Q, Xiao H, Springer C, Ehrlich G, Kamat V, Rafique A, Hu Y, Krueger P, Huang T, Poueymirou W, Babb R, Rosconi MP, Retter MW, Chen G, Morton L, Zambrowicz B, Cao J, Romano C, Olson WC.
Latuszek A, et al. Among authors: yuan m.
PLoS One. 2020 May 8;15(5):e0231892. doi: 10.1371/journal.pone.0231892. eCollection 2020.
PLoS One. 2020.
PMID: 32384086
Free PMC article.